Affiliations 

  • 1 International Medical University (IMU), Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 2 Monash University Malaysia, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia
  • 3 School of Pharmacy, International Medical University (IMU), Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 4 School of Dentistry, International Medical University (IMU), Bukit Jalil, 57000 Kuala Lumpur, Malaysia
Cancer Cell Int, 2014;14:65.
PMID: 25866477 DOI: 10.1186/1475-2867-14-65

Abstract

Epiregulin (EPR) is a novel member of the epidermal growth factor (EGF) family. It has been shown to promote wound healing in oral epithelium, enhance proliferation of other epithelial tissues, and is involved in several epithelial-related malignancies such as colorectal, lung, and bladder carcinoma. More recently, EPR transcripts were found to be high in a study on archival oral squamous cell carcinoma (OSCC) specimens. This implies that EPR may be responsible for the progression of OSCC. The aim of this was to elucidate the effects of EPR on (i) cell morphological changes, (ii) cell proliferation and (iii) receptor expression of the H-series OSCC cell lines.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.